The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy

Table 3 Estimated power based on cohort and sample size

	100	150	200	300	400	600
Melanoma Nivo 1 year PFS	0.650	0.682	0.710	0.738	0.754	0.759
Melanoma Nivo+IPI 1 year PFS	0.754	0.766	0.775	0.784	0.788	0.795
NSCLC Pembrolizumab 1 year PFS	0.732	0.750	0.764	0.776	0.782	0.790

ISSN: 1471-2407